Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT00956332
PHASE1/PHASE2

Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia

Sponsor: MultiGene Vascular Systems Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb ischemia.

Official title: Phase I/IIa Safety, Two-dose Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia

Key Details

Gender

All

Age Range

50 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2010-02

Completion Date

2026-05

Last Updated

2015-03-05

Healthy Volunteers

No

Interventions

BIOLOGICAL

MultiGeneAngio

Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

BIOLOGICAL

MultiGeneAngio

Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

Locations (7)

Barzilai Medical Center

Ashkelon, Israel

Soroka Medical Center

Beersheba, Israel

Rambam Medical Center

Haifa, Israel

Shaare Zedek Medical Center

Jerusalem, Israel

Hadassah University Hospital, Ein Kerem

Jerusalem, Israel

Kaplan Medical Center

Rehovot, Israel

Chaim Sheba Medical Center

Tel Litwinsky, Israel